Uncategorized

Roche and Nurix Therapeutics will advance their BTK degrader for chronic lymphocytic leukemia, as well as immunology and neurology indications.

After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.

Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.

After a $625 million IPO, the biggest ever in biotech, obesity-focused Kailera Therapeutics is readying a commercial strategy that puts patients at the center.

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

Si te piden que pienses en la revolución científica del siglo XVII, el primer nombre que te vendrá a la mente será, casi con total seguridad, Sir Isaac Newton. Sin embargo, a la sombra del gigante de la gravedad vivió un hombre cuya mente era tan brillante, ca&oacu …

Noticias de la actualidad astronómica y astronáutica del 8 de junio de 2026.     …

  Un acuario de agua dulce puede parecer, a simple vista, un recipiente decorativo con peces, plantas y agua limpia. Sin embargo, detrás de esa apariencia tranquila funciona un ecosistema complejo en el que intervienen microorganismos, procesos químicos, intercambio de gases, l …